Heron Therapeutics (NASDAQ: HRTX) is a commercial-stage pharmaceutical company focused on developing and commercializing products to address unmet medical needs. The filing excerpts provided do not contain sufficient detail to describe its revenue model, specific approved products, commercial infrastructure, customer base, geographic footprint, competitive position, or financial metrics with the specificity required. The 10-K was filed on 2026-02-26 (accession 000119312526073515) for the fiscal year ended December 31, 2025, and Heron is listed on the Nasdaq Capital Market. Beyond these header-level facts, the excerpts do not support additional factual claims about the business.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: ALX Oncology Holdings Inc Organogenesis Holdings Inc bluebird bio, Inc. C4 Therapeutics, Inc Cytodyn Inc Inovio Pharmaceuticals Inc Ocugen Inc Kodiak Sciences Inc Protagonist Therapeutics Inc